EU/3/19/2171

Table of contents

About

On 28 June 2019, orphan designation EU/3/19/2171 was granted by the European Commission to Dynacure S.A.S., France, for 5'-cEtG-sp-cEt5MeU-sp-cEt5MeU-sp-dT-sp-dA-sp-dT-sp-dT-sp-dA-sp-dT-sp-dA-sp-dG-sp-dG-sp-dG-sp-cEt5MeC-sp-cEt5MeU-sp-cEt5MeU-3' (also known as DYN101) for the treatment of centronuclear myopathies.

Key facts

Active substance
5'-cEtG-sp-cEt5MeU-sp-cEt5MeU-sp-dT-sp-dA-sp-dT-sp-dT-sp-dA-sp-dT-sp-dA-sp-dG-sp-dG-sp-dG-sp-cEt5MeC-sp-cEt5MeU-sp-cEt5MeU-3' (also known as DYN101)
Disease / condition
Treatment of centronuclear myopathies
Date of first decision
28/06/2019
Outcome
Positive
EU designation number
EU/3/19/2171

Sponsor's contact details

Dynacure S.A.S.
300 Boulevard Sebastien Brant
67400 Illkirch Graffenstaden
France
Tel. +33 368 854486
E-mail: info@dynacure.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating